TipRanks
Advertisement
Advertisement

VIR Stock Latest News

Vir Biotechnology seals major oncology alliance with Gilead
Company AnnouncementsVir Biotechnology seals major oncology alliance with Gilead
9d ago
8K
VIR
Vir Biotechnology enters collaboration, license agreement with Gilead
PremiumThe Fly
Vir Biotechnology enters collaboration, license agreement with Gilead
9d ago
VIR
GILD
Vir Biotechnology gains FDA Fast Track for VIR-5500
PremiumCompany Announcements
Vir Biotechnology gains FDA Fast Track for VIR-5500
15d ago
8K
VIR
Vir Biotechnology announces U.S. FDA granted FTD to VIR-5500
PremiumThe Fly
Vir Biotechnology announces U.S. FDA granted FTD to VIR-5500
15d ago
VIR
Vir Biotechnology price target raised to $22 from $20 at H.C. Wainwright
PremiumThe Fly
Vir Biotechnology price target raised to $22 from $20 at H.C. Wainwright
16d ago
VIR
Vir Biotechnology appoints Liu as Chief Medical Officer
PremiumThe FlyVir Biotechnology appoints Liu as Chief Medical Officer
16d ago
VIR
NUVB
Vir Biotechnology Appoints Aziz Sawaf as New CFO
Premium
Company Announcements
Vir Biotechnology Appoints Aziz Sawaf as New CFO
22d ago
8K
VIR
Vir Biotechnology appoints Aziz Sawaf as CFO
Premium
The Fly
Vir Biotechnology appoints Aziz Sawaf as CFO
22d ago
VIR
Vir Biotechnology in favorable position following Mirum data, says Needham
PremiumThe Fly
Vir Biotechnology in favorable position following Mirum data, says Needham
25d ago
VIR
MIRM
Analyst Reiterates Buy on Vir Biotechnology, Keeps $18 Price Target Ahead of Key HDV Phase 3 Readout
PremiumRatings
Analyst Reiterates Buy on Vir Biotechnology, Keeps $18 Price Target Ahead of Key HDV Phase 3 Readout
25d ago
VIR
Vir Biotechnology’s HBV Combo Vaccine Study Reaches Completion, Setting Up Key Pipeline Catalyst
PremiumCompany Announcements
Vir Biotechnology’s HBV Combo Vaccine Study Reaches Completion, Setting Up Key Pipeline Catalyst
2M ago
VIR
Vir Biotechnology’s Earnings Call Signals Data-Driven Momentum
PremiumCompany Announcements
Vir Biotechnology’s Earnings Call Signals Data-Driven Momentum
2M ago
VIR
Olema Oncology appoints Jason O’Byrne as CFO
PremiumThe FlyOlema Oncology appoints Jason O’Byrne as CFO
2M ago
VIR
OLMA
Analyst Reiterates Buy on Vir Biotechnology, Maintains $20 Price Target Amid Strong Late-Stage HDV Momentum and Solid Cash Runway
Premium
Ratings
Analyst Reiterates Buy on Vir Biotechnology, Maintains $20 Price Target Amid Strong Late-Stage HDV Momentum and Solid Cash Runway
2M ago
VIR
Vir Biotechnology: Buy Rating Reaffirmed on De-Risking HDV Franchise and Market-Building Tailwinds; $18 Price Target Unchanged
Premium
Ratings
Vir Biotechnology: Buy Rating Reaffirmed on De-Risking HDV Franchise and Market-Building Tailwinds; $18 Price Target Unchanged
3M ago
VIR
Vir Biotechnology price target lowered to $25 from $27 at Morgan Stanley
PremiumThe Fly
Vir Biotechnology price target lowered to $25 from $27 at Morgan Stanley
3M ago
VIR
Vir Biotechnology price target lowered to $19 from $21 at Leerink
PremiumThe Fly
Vir Biotechnology price target lowered to $19 from $21 at Leerink
3M ago
VIR
Analyst Reiterates Buy on Vir Biotechnology, Citing Advancing Hepatitis D and Oncology Pipelines and Strong Cash Runway
PremiumRatings
Analyst Reiterates Buy on Vir Biotechnology, Citing Advancing Hepatitis D and Oncology Pipelines and Strong Cash Runway
3M ago
VIR
Vir Biotechnology reports Q2 EPS 47c vs. (80c) last year
PremiumThe Fly
Vir Biotechnology reports Q2 EPS 47c vs. (80c) last year
3M ago
VIR
Vir Biotechnology Names Brent Sabatini Interim Finance Chief
PremiumCompany AnnouncementsVir Biotechnology Names Brent Sabatini Interim Finance Chief
3M ago
8K
VIR
Vir Biotechnology CFO Jason O’Byrne to depart
Premium
The Fly
Vir Biotechnology CFO Jason O’Byrne to depart
3M ago
VIR
Mirum Pharmaceuticals price target raised to $150 from $140 at Morgan Stanley
Premium
The Fly
Mirum Pharmaceuticals price target raised to $150 from $140 at Morgan Stanley
4M ago
VIR
MIRM

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >